ArticleIranian journal of child neurology2025
Exploring the Role of MEFV Gene Mutations in Pediatric Drug-Resistant Epilepsy.
Article in Iranian journal of child neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: Despite the advancements in antiepileptic drugs over the past decades, drug-resistant epilepsy (DRE) remains a significant challenge, particularly in children. Familial Mediterranean fever (FMF), attributed to mutations in the Mediterranean fever (MEFV) gene, has been linked to various neurological disorders, including seizures. This study investigates the potential association between MEFV gene mutations and DRE and evaluates their impact on the disease course. Materials & Methods: A case-control study was conducted involving 22 children under 18 years of age with DRE, referred to the Pediatric Neurology Clinic of Children's Medical Center, Tehran, Iran, between March 2021 and March 2022. The control group comprised 30 healthy individuals randomly selected from the FMF database of Ardabil University, Iran. Relevant information, including age, demographics, disease characteristics, and treatment details, was collected using a structured form. Blood samples were analyzed for 12 common MEFV gene mutations. Results: Out of 52 subjects, the case group consisted of 22 children diagnosed with DRE, compared to 30 patients without FMF in the control group. The mean age of the case group was 9.2 ± 4.5 years, with a mean age at seizure onset of 38.13 ± 32.21 months. MEFV mutations were identified in eight patients (15.4%), with seven in the control group and one (4.5%) in the case group. However, the difference in MEFV gene mutations between the case and control groups did not reach statistical significance (P=0.13). Conclusion: The prevalence of MEFV gene mutations in children with DRE was 4.5%, suggesting that these mutations may not significantly influence the occurrence of DRE in this population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.